Partial
Needs Revision
Patient Risk:
Low
Summary
The response accurately identifies rivaroxaban as the active ingredient in XARELTO and is directionally consistent with the label's description of rivaroxaban as an orally administered factor Xa inhibitor. However, the claims about generic availability, patents, exclusivity, manufacturers, launch timing, and the FDA Orange Book are not addressed in the supplied prescribing information.
Category Scores
Accurate Statements
Xarelto is rivaroxaban.
Section 11 states that rivaroxaban is the active ingredient in XARELTO.
Unsupported Statements
Rivaroxaban is a direct oral anticoagulant.
The label identifies rivaroxaban as a selective factor Xa inhibitor and describes oral XARELTO products, but it does not use or define the term 'direct oral anticoagulant.'
The availability and launch timing of generic rivaroxaban depend on patent and exclusivity status and the country.
The supplied label does not address patents, exclusivity, generic availability, launch timing, or country-specific availability.
Generic availability may vary by dosage, including 2.5 mg, 10 mg, 15 mg, and 20 mg strengths, and by manufacturer.
Section 11 lists those XARELTO tablet strengths but does not address generic availability, manufacturer variation, or dosage-specific generic status.
The FDA Orange Book lists current patent and exclusivity status and approved generic versions of rivaroxaban in the United States.
The supplied prescribing information does not mention the FDA Orange Book, patent or exclusivity listings, or approved generic versions.
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The claims do not provide dosing, administration, treatment, or safety instructions. The main issue is that several market and regulatory claims are outside the supplied label, rather than a direct patient-safety error.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Needs Revision
Primary Issue
Most claims concerning generic availability and the FDA Orange Book are not supported by the supplied prescribing information.
Suggested Improvement
Limit label-based statements to the identification of rivaroxaban as the active ingredient in XARELTO and its description as a factor Xa inhibitor in oral products. Clearly identify any patent, exclusivity, generic-availability, manufacturer, or Orange Book information as external to the prescribing information.